Navigation Links
Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Date:9/25/2007

e to 5-FU/LV," said Lars Birgerson, Vice President, Medical Affairs, Roche. "Roche is committed to providing colon cancer patients with the safest and most effective treatment options that allow patients to continue their active lifestyles."

Colorectal cancer is the third most common cancer in the United States. The American Cancer Society estimates that in 2007 more than 153,500 people in the U.S. will be diagnosed and about 52,000 people will die from the disease, accounting for almost 10 percent of all cancer deaths. When colorectal cancer is detected at an early, localized stage, the five-year survival is 90 percent; however, only 39 percent of colorectal cancers are diagnosed at this stage, mostly due to low rates of screening.

About the X-ACT Trial

The international, Phase III X-ACT trial enrolled 1,987 patients (1,004 patients were randomly assigned to Xeloda; 983 patients were assigned to intravenous 5-FU/LV) who were treated for a period of 24 weeks between 1998 and 2001 at 164 centers worldwide. The primary study objective was to show equivalence in disease-free survival between Xeloda and intravenous 5-FU/LV. Secondary objectives included: relapse-free survival, overall survival and safety.

Xeloda three-year disease-free survival and relapse-free survival rates demonstrated non-inferiority to 5-FU/LV (intent-to-treat analysis, P < 0.0001; P=0.0407, respectively). Xeloda was associated with fewer adverse events than 5-FU/LV (P < 0.001).

With a median follow-up of 7 years, updated study results presented at ECCO show five-year overall survival rates for Xeloda at 71.4 percent compared to 68.4 percent in the 5-FU/LV arm.

About Xeloda

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill form, Xeloda is enzymatically activated within the body; when it comes into contact with a naturally occurring protein called thymidine phos
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... BAUDETTE, Minn., May 5, 2015  ANI Pharmaceuticals, Inc. ... for the three months ended March 31, 2015 and ... share guidance for 2015. First Quarter 2015 ... $18.8 million, an increase of 72% as compared to $10.9 ... First quarter adjusted non-GAAP EBITDA of $11.5 million, an increase ...
(Date:5/5/2015)... , May 5, 2015 ... "the Group"), the regenerative medical devices company, announces ... new regional distribution contract for DermaPure® which is ... wounds.      (Logo: http://photos.prnewswire.com/prnh/20150505/743321) , ... Dermapure® since Tissue Regenix received notice of Local ...
(Date:5/5/2015)...  Stryker Orthopaedics announced today its return to THE ...  Since becoming the "Official Joint Replacement Products of ... ago, the company has made 14 stops along the ... activation the Stryker Mobility Zone – a destination designed ... health. Proving to be a successful program, Stryker has ...
Breaking Medicine Technology:ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 2ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 3ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 4ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 5ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 6ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 7ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 8ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 9Tissue Regenix Group plc: US Regional Distribution Agreement Signed 2Stryker Returns to TPC Sawgrass for THE PLAYERS Championship Alongside Former Tournament Winners Fred Funk and Hal Sutton 2Stryker Returns to TPC Sawgrass for THE PLAYERS Championship Alongside Former Tournament Winners Fred Funk and Hal Sutton 3
... 2012  MModal Inc. (NASDAQ/GS: MODL), a leading provider of ... and clinical documentation workflow, today announced details for the ... 31, 2011.  M*Modal plans to issue ... the market closes on Wednesday, March 7, 2012, and ...
... WOODLANDS, Texas, Feb. 16, 2012   Lexicon Pharmaceuticals, Inc. ... focused on discovering breakthrough treatments for human disease, will ... results on Wednesday, February 22, 2012 before the financial ... and webcast to discuss clinical development progress and financial ...
Cached Medicine Technology:Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012 2
(Date:5/5/2015)... This year, PolyU researchers garnered two Grand Prizes, ... Gold Medals and four Silver Medals at the world-renowned ... (1) Grand Prize and Gold Medal with the Congratulations ... Fitting, Principal Investigator: Dr Allan Chee-kooi CHAN, Institute of ... much on the “mannequin” for many tasks involved in ...
(Date:5/5/2015)... 05, 2015 ProTexting, LLC – ... to deploy Mobile Engagement Campaigns and other Mobile solutions, ... clients can now leverage the power of Mobile Marketing ... syncing subscribers’ e-mail addresses into the Constant Contact Platform. ... that the growing trend of multi-channel marketing would become ...
(Date:5/5/2015)... 2015 Rare Genomics Institute ... study aimed at determining how crowdfunding can promote scientific ... international non-profit providing rare disease patients with access to ... scientists and researchers, and help for payment of these ... excited to see how crowdfunding will not only help ...
(Date:5/5/2015)... California (PRWEB) May 05, 2015 On ... Downtown Los Angeles, CA, Choices Recovery sponsored Durkin Entertainment’s ... Durkin, LA’s leading producer of sustainable product placement in ... of the world’s top providers of ecologically sound and ... a premier red carpet event that makes appearances at ...
(Date:5/5/2015)... 2015 RF Technologies®, a leading provider ... ST750 Fall Management Solution with Voice Alarms. The ST750 ... or resident to wait for assistance when it detects ... choice of 16 different melodies or tones or silent ... such as Code Alert®. , For 28 years, ...
Breaking Medicine News(10 mins):Health News:PolyU wins top prizes in Geneva’s Invention Expo 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 3Health News:PolyU wins top prizes in Geneva’s Invention Expo 4Health News:PolyU wins top prizes in Geneva’s Invention Expo 5Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3Health News:Rare Genomics Institute to Study Impact of Crowdfunding on Rare Diseases 2Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 3
... America, Inc. (SAI),today announced the 1,000th activation ... Hagerstown Medical Laboratory, Maryland.,SNCS is a remote ... tracks instrument performance data from Sysmex analyzers ... SNCS enables proactive response to potential,instrument problems, ...
... Medications May Disappear or be Hindered For ... California,s Most Vulnerable Citizens, SACRAMENTO, Calif., ... against the California Department of,Health Care Services and its director ... pharmacies from going into effect on July 1,2008. The action ...
... Raising Awareness ... & Education, NEW YORK, June 10 MGM ... branding initiative, PiNKiTUDE, which,will encompass a wide range of ... earmarked for the global breast cancer organization,Susan G. Komen ...
... June 5, 2008 Over 1.3 million Americans ... of the joints. RA is a disabling condition, and ... pain and loss of function in affected areas. A ... Journal of Periodontology , the official publication of ...
... regimen of the immune-suppressing drug cyclophosphamide seems to slow ... small group of patients studied and may even restore ... report. The findings in nine people, most of whom ... treat a disease that tends to progress relentlessly. , ...
... Promote Health and ... Wellness, ... meeting consumers, health and wellness needs, the Kellogg,Company joined the Department of ... companies,promoting eating and physical fitness for families that is consistent with,MyPyramid. The ...
Cached Medicine News:Health News:Sysmex America to Enable Prolonged Hematology Instrument Uptime for Hagerstown Medical Laboratory With 1,000th SNCS Activation 2Health News:Sysmex America to Enable Prolonged Hematology Instrument Uptime for Hagerstown Medical Laboratory With 1,000th SNCS Activation 3Health News:Eight California Pharmacies File Lawsuit Against the California Department of Health Care Services to Stop the 10 Percent Medi-Cal Provider Cuts to Pharmacies 2Health News:PiNKiTUDE, New Cause Marketing Initiative Inspired by MGM's Pink Panther, Benefits Susan G. Komen for the Cure(R) 2Health News:PiNKiTUDE, New Cause Marketing Initiative Inspired by MGM's Pink Panther, Benefits Susan G. Komen for the Cure(R) 3Health News:PiNKiTUDE, New Cause Marketing Initiative Inspired by MGM's Pink Panther, Benefits Susan G. Komen for the Cure(R) 4Health News:Researchers uncover higher prevalence of periodontal disease in rheumatoid arthritis patients 2Health News:'HiCy' drug regimen reverses ms symptoms in selected patients 2Health News:'HiCy' drug regimen reverses ms symptoms in selected patients 3Health News:Kellogg and MyPyramid - Helping Families Live Well Today and Every Day 2Health News:Kellogg and MyPyramid - Helping Families Live Well Today and Every Day 3Health News:Kellogg and MyPyramid - Helping Families Live Well Today and Every Day 4
Each slide contains a gram positive control of Staphylococcus aureus ATCC ® 25923, a gram negative control of Escherichia coli ATCC ® 25922 and areas for three clinical specimens. Ideal for s...
... The Equalizer With 384 Well Plate ... the revolutionary features of the original Equalizerexpandable and ... autoclavable components, and in-lab calibration capabilities. In addition, ... tips down to 4.5mm for loading and accessing ...
... Plate Capability The Equalizer 384 includes ... and equal tip spacing, choice of two software ... addition, this model allows you to evenly space ... accessing many gels and for use with 384 ...
... Equalizer With 384 Well Plate Capability ... of the original Equalizerexpandable and equal tip spacing, ... in-lab calibration capabilities. In addition, this model allows ... 4.5mm for loading and accessing many gels and ...
Medicine Products: